GeneTether Therapeutics Inc.
GeneTether Therapeutics Inc.
![GeneTether Therapeutics Inc. logo](https://webfiles.thecse.com/CSE_Listed_On_Graphics-07-TM-RGB-GTTX-08.png?0YqR_r25NJruFvyMInBJXD8ZBl8IzLeF)
CSE Index:
Currency:
GeneTether Therapeutics is an innovative genetic medicines company focused on creating best-in-class gene editing therapies based on our proprietary GeneTether™ platform. Our platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We use a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage.
GeneTether Therapeutics Inc. (GTTX)
SEDAR Information
Company Info
Address
301-1665 Ellis Street
Kelowna, BC V1Y 2B3
CanadaPhone
(514) 796-2640Email
[email protected]Website
https://www.genetether.comListing date
Monday, March 28, 2022Transfer Agent
Odyssey Trust CompanyCapitalization
Issued & Outstanding:
38744674Reserved for Issuance:
17942855Company Officers
Roland Boivin, Chief Executive Officer
Daren Graham, Chairman
R. Geoffrey Sargent, Chief Scientific Officer
Jean Jen, Chief Financial Officer and Corporate Secretary
Bulletins
28/03/2022
2022-0339 - New Listing - GeneTether Therapeutics Inc. (GTTX)
le 28 mars/March 2022
The common shares of GeneTether Therapeutics Inc., have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.